c) a radical R^3 is converted into another radical R^3 by

i) converting a carboxylic group into an amide,
ii) acylating or alkylating an amino group,

or

d) that a compound of formula I is liberated from one of its functional derivatives by treatment with a solvolysing or hydrogenolysing agent, and/or a base or acid of the formula I is converted into one of its salts.

9. At least one compound of the formula I according to claim 1, and/or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, and optionally a pharmaceutically acceptable carrier, excipient or vehicle for use as a medicament.

10. Use of a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof, including mixtures thereof in all ratios, in the manufacture of a medicament for the treatment and/or prevention of cancer.

11. The use according to claim 10, wherein the cancer is a gastrointestinal stromal tumor.

12. At least one compound of the formula I according to claim 1, and/or a pharmaceutically acceptable salt, solvate and stereoisomer thereof, including mixtures thereof in all ratios, for use as a medicament together with at least one further active ingredient as a medicament.

13. A set or kit consisting of separate packs of

(a) an effective amount of a compound of the formula I according to claim 1, and/or a pharmaceutically acceptable salt, solvate, salt or stereoisomer thereof, including mixtures thereof, and

(b) an effective amount of a further active ingredient in the form of a medicament.